9-ING-41

9-ING-41 是基于马来酰亚胺的 ATP 竞争性和选择性的糖原合酶激酶-3β 抑制剂,IC50为 0.71 μM。它显著导致癌细胞的细胞周期停滞,自噬和凋亡,具有增强化疗药物抗肿瘤作用的潜力,有抗癌活性。

CAS号

1034895-42-5

分子式

C22H13FN2O5

主要靶点

Apoptosis|GSK-3|Autophagy

仅限科研使用

Cat No : CM04319

Print datasheet

Synonyms



产品信息

9-ING-41 is a glycogen synthase kinase-3 inhibitor.

CAS号 1034895-42-5
分子式 C22H13FN2O5
主要靶点 Apoptosis|GSK-3|Autophagy
主要通路 PI3K/Akt/mTOR信号通路|凋亡|自噬|干细胞
分子量 404.35
纯度 99.25%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名

靶点活性

GSK-3β:0.71 μM (IC50)

体内活性

In a mouse model of MCL, 9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity [2].

体外活性

9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM[2].

溶解度

DMSO:97 mg/mL (239.89mM),Sonification is recommended.

参考文献

1.Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. 2.Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2